Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses

Reuters

09/05

Capricor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses

Capricor Therapeutics Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi & Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069246) on September 05, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2565550853"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565550853\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565550853?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565550853","market":"fut","top_or_hot":-1,"title":"Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CAPR\">Capricor Therapeutics Inc</a>. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi &amp; Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069246) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCapricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-05 19:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CAPR\">Capricor Therapeutics Inc</a>. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi &amp; Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069246) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL6VV7J4:1","article_id":"2565550853","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565550853","pubTimestamp":1757072836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Capricor Therapeutics Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi & Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CAPR":"Capricor Therapeutics Inc"},"translate_title":"Capricor Therapeutics因涉嫌证券欺诈和投资者损失面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":0.9},"content_text":"Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses\n    \n\nCapricor Therapeutics Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi & Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069246) on September 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}